中国当代儿科杂志2025，Vol.27Issue(6)：690-695,6.DOI:10.7499/j.issn.1008-8830.2410063
血清CD4+和NK细胞预测儿童再生障碍性贫血治疗效果的临床意义
Prognostic value of serum CD4+and NK cells for the treatment response in children with aplastic anemia
摘要
Abstract
Objective To evaluate the clinical value of CD4⁺ cell percentage(CD4⁺%)and NK cell percentage(NK%)in predicting treatment outcomes in children with aplastic anemia(AA),providing a reference for precise diagnosis and treatment.Methods This retrospective study analyzed the clinical data of AA children treated with cyclosporine A at the First Affiliated Hospital of Xinjiang Medical University from January 2019 to April 2024.The study involved 48 AA children as the observation group and 50 children undergoing medical check-ups during the same period as the control group.Lymphocyte subset data were collected from both groups to analyze differences and their relationship with treatment efficacy.Based on hematological responses,the observation group was divided into an effective group of 18 patients(HR group,including complete and partial remission)and an ineffective group of 30 patients(NHR group,including non-remission).Results Univariate analysis showed that NK%in the observation group was significantly lower than that in the control group(P<0.05).The observation group was followed up for 3 months.The HR group had a lower CD4⁺%than the NHR group(P=0.018)and a higher NK%than the NHR group(P=0.029).Multivariate logistic regression analysis indicated that a high CD4⁺%was a risk factor for poor treatment efficacy(OR=1.062),whereas a high NK%was a protective factor(OR=0.820).The area under the curve for the prediction of HR in pediatric AA by combining CD4⁺%and NK%was 0.812.Conclusions A higher CD4⁺%at diagnosis is a predictor of poor treatment response,whereas a higher NK%is associated with better outcomes.关键词
再生障碍性贫血/血液学反应/CD4+细胞/NK细胞/儿童Key words
Aplastic anemia/Hematological response/CD4+cell/NK cell/Child引用本文复制引用
吴春灿,严媚,海力其古丽·努日丁,马旭凯,刘玉..血清CD4+和NK细胞预测儿童再生障碍性贫血治疗效果的临床意义[J].中国当代儿科杂志,2025,27(6):690-695,6.基金项目
"天山英才"医药卫生高层次人才培养计划(TSYC202301A002) （TSYC202301A002）
"青年科研起航"专项基金,(2023YFY-QKQN-09) （2023YFY-QKQN-09）
免疫性疾病研究槐杞黄专项基金(CXPJJH122003-55) （CXPJJH122003-55）
儿童重大疾病基础研究、专病队列研究以及预警模型构建研究(2024B03038). （2024B03038）
